Stock Events

Stock Events

Amicus Therapeutics 

$14.48
0
+$0.55+3.95% Tuesday 04:00

Statistics

Day High
14.48
Day Low
14.48
52W High
-
52W Low
-
Volume
2
Avg. Volume
-
Mkt Cap
4.55B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
0.01
0.03
0.05
0.07
Expected EPS
0.03
Actual EPS
N/A

Financials

-4.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.27BRevenue
-54.22MNet Income

Analyst Ratings

$14.67Average Price Target
The highest estimate is 19.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
14%
Hold
86%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FOLD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Amicus Therapeutics' focus on rare and orphan diseases.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the biotechnology space, particularly in developing therapies for neurological and neurodegenerative diseases, overlapping with some of Amicus' therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapies for genetic diseases, directly competing with Amicus' gene therapy approaches for similar conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, closely competing with Amicus Therapeutics' product portfolio.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics specializes in precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, competing with Amicus' focus on rare genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which competes with Amicus' efforts in developing therapies for rare genetic conditions.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its advanced therapy platforms, competes in the same space as Amicus, particularly in gene therapies and treatments for rare diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a growing interest in rare diseases and gene therapy, making it a competitor as it expands its portfolio in areas that overlap with Amicus Therapeutics' focus.

About

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Show more...
CEO
ISIN
US03152W1099

Listings

BOATS
BOATS
FOLD.BOATS
XNAS
US
FOLD
MX
MX
FOLD.MX
LSE
GB
0HF9.LSE

0 Comments

Share your thoughts

FAQ

What is Amicus Therapeutics stock price today?▼
The current price of FOLD.BOATS is $14.48 USD — it has increased by +3.95% in the past 24 hours. Watch Amicus Therapeutics stock price performance more closely on the chart.
What is Amicus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amicus Therapeutics stocks are traded under the ticker FOLD.BOATS.
What is Amicus Therapeutics market cap?▼
Today Amicus Therapeutics has the market capitalization of 4.55B
When is the next Amicus Therapeutics earnings date?▼
Amicus Therapeutics is going to release the next earnings report on May 13, 2026.
What were Amicus Therapeutics earnings last quarter?▼
FOLD.BOATS earnings for the last quarter are 0.01 USD per share, whereas the estimation was 0.07 USD resulting in a -86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amicus Therapeutics revenue for the last year?▼
Amicus Therapeutics revenue for the last year amounts to 1.27B USD.
What is Amicus Therapeutics net income for the last year?▼
FOLD.BOATS net income for the last year is -54.22M USD.
When did Amicus Therapeutics complete a stock split?▼
Amicus Therapeutics has not had any recent stock splits.